09:29 AM EDT, 10/17/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Friday that a new post-hoc analysis of a late-stage study showed "clinically meaningful" improvements in tardive dyskinesia symptoms in patients treated with Ingrezza at the lowest available dose of 40 mg.

The company said 90% of participants who received continuous treatment for 48 weeks improved by at least 50% on the Abnormal Involuntary Movement Scale Total Score.

Patients who lowered their dose to 40 mg from 80 mg for tolerability reasons experienced similar therapeutic benefits, the company said.

Efficacy outcomes with the 40 mg dose were comparable with those of the 80 mg dose in the original late-stage study, Neurocrine said.

The study showed that safety and tolerability of treatment were consistent with Ingrezza's known profile, the company said.